Tadnersen

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTadnersen
Drug Alias NameBIIB-078 free acidTadnersen sodiumBIIB-078IONIS-BIIB-5RxIONIS-C9Rx
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionGuanine nucleotide exchange C9orf72 modulators
TargetsGuanine nucleotide exchange C9orf72
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen Inc
Active IndicationsN/A
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A